In a 72-year-old patient with impaired renal function (eGFR 34 mL/min/1.73 m²) taking metformin 500 mg daily (A1c 6.8 %) and metoprolol 100 mg twice daily for atrial fibrillation, is dapagliflozin 10 mg daily safe to start?

Yes, dapagliflozin 10 mg is safe to start in this patient with eGFR 34 mL/min/1.73 m²

Dapagliflozin 10 mg daily is appropriate and recommended for this 72-year-old patient with Stage 3b CKD (eGFR 34), type 2 diabetes, and atrial fibrillation, as the eGFR is above the 25 mL/min/1.73 m² threshold for initiation. 1

Guideline-Based Recommendation

The 2022 ADA/KDIGO consensus guidelines explicitly state that an SGLT2 inhibitor with proven kidney or cardiovascular benefit is recommended for patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m². 1 For dapagliflozin specifically:

• Approved dose at eGFR 30-44 mL/min/1.73 m²: 10 mg daily 1
• Initiation is not recommended only when eGFR falls below 25 mL/min/1.73 m² 1
• Once started, dapagliflozin can be continued even if eGFR declines further, until dialysis 1

The FDA label confirms dapagliflozin is approved for use at 10 mg once daily with eGFR ≥25 mL/min/1.73 m² for cardiovascular and kidney protection, though glucose-lowering efficacy diminishes below 45 mL/min/1.73 m². 2

Why This Patient Benefits

This patient has multiple indications for SGLT2 inhibitor therapy:

• Type 2 diabetes with CKD (primary indication)
• Atrial fibrillation (cardiovascular disease present)
• eGFR 34 places him in the range where kidney and cardiovascular benefits are preserved even though glucose-lowering effects are reduced 1

The DAPA-CKD trial demonstrated that dapagliflozin significantly reduces the risk of sustained eGFR decline ≥50%, end-stage kidney disease, and cardiovascular/renal death (HR 0.61, P<0.001) in patients with CKD and eGFR as low as 25 mL/min/1.73 m². 3

Metformin Consideration

The current metformin dose (500 mg daily) should be reviewed. At eGFR 34 mL/min/1.73 m² (Stage 3b CKD), guidelines recommend reducing metformin to a maximum of 1000 mg/day. 1 Since this patient is only on 500 mg daily, the dose is appropriate and does not need adjustment. However, metformin becomes contraindicated if eGFR drops below 30 mL/min/1.73 m². 1

No Drug Interaction Concerns

Metoprolol for atrial fibrillation does not interact with dapagliflozin. There are no contraindications to combining these medications.

Critical Safety Monitoring

When initiating dapagliflozin in this patient, monitor for:

Volume Status

• Assess for volume depletion before starting 1, 2
• The patient is on metoprolol (beta-blocker), which may mask tachycardia from volume depletion
• Consider whether diuretics are also prescribed—if so, may need dose reduction 1
• Follow-up within 2-4 weeks to reassess blood pressure and volume status

Expected eGFR Dip

• An acute, reversible decline in eGFR of >10% within the first 2 weeks is common and expected 4
• This does NOT indicate harm—patients experiencing this acute dip actually had better long-term kidney protection in DAPA-CKD 4
• Do not discontinue dapagliflozin for this expected eGFR change
• Recheck eGFR at 2-4 weeks, then as clinically indicated 2

Hypoglycemia Risk

• At A1c 6.8%, hypoglycemia risk is LOW 1
• Metformin does not cause hypoglycemia
• No insulin or sulfonylurea in the regimen
• Background therapy adjustment is generally not required 1

Genital Mycotic Infections

• Counsel on daily genital hygiene 1
• Risk is 6% vs 1% with placebo, higher in women 1

Diabetic Ketoacidosis (DKA)

• Risk is very low in type 2 diabetes without insulin 1
• Educate on sick-day protocol: hold dapagliflozin during acute illness, prolonged fasting, or before surgery (3-4 days) 2
• Watch for euglycemic DKA (nausea, vomiting, abdominal pain, shortness of breath) even with glucose <250 mg/dL 2

Common Pitfall to Avoid

Do not withhold dapagliflozin because glucose-lowering efficacy is reduced at this eGFR. The primary benefit at eGFR 34 is kidney and cardiovascular protection, not glycemic control. 1 The A1c of 6.8% is already at goal, so the cardiorenal benefits are the therapeutic priority here.

The 2022 guidelines emphasize that glucose-lowering efficacy diminishes as eGFR declines, but kidney and cardiovascular benefits are preserved even at lower eGFR levels. 1 This patient should continue dapagliflozin even if eGFR declines further, as long as it's tolerated, until dialysis is initiated. 1